Radiopharm Theranostics Limited
Income Statement
| Line Item | FY2025 |
|---|---|
| Revenue | $3.6M |
| Cost of Revenue | $3.6M |
| Gross Profit | $39.3K |
| Gross Margin | 1.1% |
| Operating Expenses | |
| Research & Development | — |
| SG&A Expense | — |
| Operating Income | $-38.2M |
| Operating Margin | -1,050.6% |
| Interest Expense | — |
| Pretax Income | $-38.2M |
| Income Tax Expense | $103.3K |
| Net Income | $-38.3M |
| Net Margin | -1,055.3% |
| EPS (Basic) | $-1.76 |
| EPS (Diluted) | $-1.76 |
| Shares Outstanding (Basic) | 2.36B |
| Shares Outstanding (Diluted) | 2.36B |
| Dividends Per Share | — |